These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38772678)

  • 21. A case of hypogammaglobulinemia with enteroviral meningoencephalitis, associated with increased adenosine deaminase in cerebrospinal fluid.
    Alborizi A; Hosseini-nasab A; Zeyaeian M; Sanaei A; Kashef S
    Iran J Allergy Asthma Immunol; 2009 Jun; 8(2):117-9. PubMed ID: 19671942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.
    Hassan R; Williams-Gould J; Watson T; Pai-Scherf L; Pastan I
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):16-8. PubMed ID: 14734446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients.
    Levi ME; Quan D; Ho JT; Kleinschmidt-Demasters BK; Tyler KL; Grazia TJ
    Clin Transplant; 2010; 24(2):223-8. PubMed ID: 19659514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
    Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
    Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD.
    Mears V; Jakubecz C; Seeco C; Woodson S; Serra A; Abboud H
    J Neuroimmunol; 2023 Apr; 377():578066. PubMed ID: 36917920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Agammaglobulinemia with the absence of circulating B-lymphocytes. 9 cases].
    Bejaoui M; Barbouche MR; Mellouli F; Tirellil N; Dellagi K
    Presse Med; 1998 Mar; 27(12):562-6. PubMed ID: 9767948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of multiple sclerosis with anti-CD20 antibodies.
    Barun B; Bar-Or A
    Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice.
    Kolomansky A; Kaye I; Ben-Califa N; Gorodov A; Awida Z; Sadovnic O; Ibrahim M; Liron T; Hiram-Bab S; Oster HS; Sarid N; Perry C; Gabet Y; Mittelman M; Neumann D
    Front Immunol; 2020; 11():561294. PubMed ID: 33193330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of enterovirus RNA in cerebrospinal fluid: comparison of two molecular assays.
    de Crom SC; Obihara CC; van Loon AM; Argilagos-Alvarez AA; Peeters MF; van Furth AM; Rossen JW
    J Virol Methods; 2012 Jan; 179(1):104-7. PubMed ID: 22024398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enteroviral Meningoencephalitis as a Complication of Rituximab Therapy for Rheumatoid Arthritis.
    Cook SG; Ford AW; Lindholm DA; Scott J
    Cureus; 2021 Sep; 13(9):e18189. PubMed ID: 34707960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic Analysis of Cerebrospinal Fluid in Children with Acute Enterovirus-Associated Meningoencephalitis Identifies Dysregulated Host Processes and Potential Biomarkers.
    Sun Z; Li W; Xu J; Ren K; Gao F; Jiang Z; Ji F; Pan D
    J Proteome Res; 2020 Aug; 19(8):3487-3498. PubMed ID: 32678604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
    Braza MS; Klein B; Fiol G; Rossi JF
    Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy.
    Ganjoo KN; Raman R; Sobel RA; Pinto HA
    Leuk Lymphoma; 2009 Apr; 50(4):673-5. PubMed ID: 19373672
    [No Abstract]   [Full Text] [Related]  

  • 37. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.
    Colucci M; Carsetti R; Serafinelli J; Rocca S; Massella L; Gargiulo A; Lo Russo A; Capponi C; Cotugno N; Porzio O; Onetti Muda A; Palma P; Emma F; Vivarelli M
    Front Immunol; 2019; 10():1653. PubMed ID: 31379849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
    Mössner E; Brünker P; Moser S; Püntener U; Schmidt C; Herter S; Grau R; Gerdes C; Nopora A; van Puijenbroek E; Ferrara C; Sondermann P; Jäger C; Strein P; Fertig G; Friess T; Schüll C; Bauer S; Dal Porto J; Del Nagro C; Dabbagh K; Dyer MJ; Poppema S; Klein C; Umaña P
    Blood; 2010 Jun; 115(22):4393-402. PubMed ID: 20194898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.